Ovid Therapeutics Files 8-K on Security Holder Matters

TL;DR

Ovid Therapeutics filed an 8-K for shareholder votes. Keep an eye on governance.

AI Summary

Ovid Therapeutics Inc. filed an 8-K on July 10, 2025, reporting on the submission of matters to a vote of security holders. The filing details events that occurred on or before July 9, 2025. The company is incorporated in Delaware and its principal executive offices are located in New York, NY.

Why It Matters

This filing indicates that Ovid Therapeutics is engaging in corporate governance activities requiring shareholder input, which could impact future strategic decisions or company direction.

Risk Assessment

Risk Level: low — The filing is a routine corporate disclosure regarding shareholder matters and does not appear to contain significant new financial or operational risks.

Key Players & Entities

• Ovid Therapeutics Inc. (company) — Registrant
• July 10, 2025 (date) — Filing Date
• July 9, 2025 (date) — Date of Earliest Event Reported
• Delaware (jurisdiction) — State of Incorporation
• New York, New York (location) — Principal Executive Offices

FAQ

From the Filing

0001628280-25-034733.txt : 20250710 0001628280-25-034733.hdr.sgml : 20250710 20250710162955 ACCESSION NUMBER: 0001628280-25-034733 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20250710 ITEM INFORMATION: Submission of Matters to a Vote of Security Holders FILED AS OF DATE: 20250710 DATE AS OF CHANGE: 20250710 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Ovid Therapeutics Inc. CENTRAL INDEX KEY: 0001636651 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 465270895 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38085 FILM NUMBER: 251116593 BUSINESS ADDRESS: STREET 1: 441 NINTH AVENUE, 14TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10001 BUSINESS PHONE: 212-776-4381 MAIL ADDRESS: STREET 1: 441 NINTH AVENUE, 14TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10001 8-K 1 ovid-20250710.htm 8-K ovid-20250710 0001636651 false 0001636651 2024-03-08 2024-03-08 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 9, 2025 OVID THERAPEUTICS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38085 46-5270895 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.)       441 Ninth Avenue , 14th Floor New York , New York 10001 (Address of Principal Executive Offices)    (Zip Code) Registrant’s Telephone Number, Including Area Code: 646 - 661-7661 Not Applicable (Former Name or Former Address, if Changed Since Last Report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below): ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, par value $0.001 per share   OVID   The Nasdaq Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Item 5.07.    Submission of Matters to a Vote of Security Holders. Ovid Therapeutics Inc. (the “ Company ”) held its annual meeting of stockholders (the “ Annual Meeting ”) on July 9, 2025. As of May 19, 2025, the record date for the Annual Meeting, there were 71,109,514 shares of Company common stock outstanding and entitled to vote on the proposals presented at the Annual Meeting, of which 55,992,587 shares, or 78.74%, were present in person or represented by proxy, which constituted a quorum. Summarized below are descriptions of the proposals voted on at the Annual Meeting and the final results for each of the proposals. The proposals set forth below are described in detail in the Company’s definitive proxy statement filed with the Securities and Exchange Comm